EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Early response monitoring during [177Lu]Lu-PSMA I&T therapy with quantitated SPECT/CT predicts overall survival of mCRPC patients: subgroup analysis of a Swiss-wide prospective registry study

Moritz C Neubauer, Guillaume P Nicolas, Andreas Bauman, Melpomeni Fani, Egbert Nitzsche, Ali Afshar-Oromieh, Flavio Forrer, Cyril Rentsch, Frank Stenner, Arnoud Templeton, Niklaus Schäfer, Damian Wild und 2 weitere

European Journal of Nuclear Medicine and Molecular Imaging · 2024-03 · 51 (4) · 1185-1193

DOI: 10.1007/s00259-023-06536-2 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 01.12.2023. Verfasst von Moritz C Neubauer und 13 weiteren Autor:innen. Beteiligte Einrichtung: Clinic for Radiology and Nuclear Medicine, University Hospital Basel, Petersgraben 4, 4051, Basel, Switzerland. moritzchristian.neubauer@usb.ch. Hauptthemen laut MEDLINE: Prostate-Specific Antigen, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: swissHADRON foundation, Siemens Healthineers, University of Basel.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To assess early tumor response with quantitated SPECT/CT and to correlate it with clinical outcome in metastatic castration–resistant prostate cancer (mCRPC) patients treated with 177 Lutetium-PSMA I&T therapy.

Methods

Single-center, observational study, part of the prospective Swiss national cancer registry study investigating the safety and efficacy of [ 177 Lu]Lu-PSMA I&T (EKNZ: 2021–01271) in mCRPC patients treated with at least two cycles of [ 177 Lu]Lu-PSMA I&T 6-weekly. After the first and second cycle quantitated SPECT/CT (Symbia Intevo, Siemens) was acquired 48 h after injection (three fields of view from head to thigh, 5 s/frame) and reconstructed using xQuant® (48i, 1 s, 10-mm Gauss). Image analysis: The PSMA-positive total tumor volumes (TTV) were semi-automatically delineated using a SUV threshold of 3 with MIMencore® (version 7.1.3, Medical Image Merge Software Inc.). Changes in TTV, highest tumor SUVmax, and total tumor SUVmean between cycles 1 and 2 were calculated and grouped into a) stable or decrease and b) increase. Serum PSA levels were assessed at each therapy cycle and at follow-up until progression or death. Changes in TTV, PSA, SUVmax, and SUVmean were correlated with PSA-progression-free survival (PSA-PFS) and the overall survival (OS) using the Kaplan–Meier methodology (log-rank test).

Results

Between 07/2020 and 04/2022, 111 patients were screened and 73 finally included in the data analysis. The median follow-up was 8.9 months (range 1.4–26.6 months). Stable or decreased TTV at cycle 2 was associated with longer OS (hazard ratio (HR) 0.28, 95% confidence interval (CI) 0.09–0.86, p < 0.01). Similar, stable, or decreased PSA was associated with longer OS (HR 0.21; CI 0.07–0.62, p < 0.01) and PSA-PFS (HR 0.34; 95% CI 0.16–0.72, p < 0.01). Combining TTV and PSA will result in an augmented prognostic value for OS (HR 0.09; CI 0.01–0.63; p < 0.01) and for PSA-PFS (HR 0.11; CI 0.02–0.68; p < 0.01). A reduction of SUVmax or SUVmean was not prognostically relevant, neither for OS ( p 0.88 and 0.7) nor for PSA-PFS ( p 0.73 and 0.62, respectively).

Conclusion

Six weeks after initiating [ 177 Lu]Lu-PSMA I&T, TTV and serum PSA appear to be good prognosticators for OS. Combined together, TTV + PSA change demonstrates augmented prognostic value and can better predict PSA-PFS. Larger studies using TTV change prospectively as an early-response biomarker are warranted for implementing management change towards a more personalized clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostate-Specific AntigenProstatic Neoplasms, Castration-ResistantMaleHumansSwitzerlandSingle Photon Emission Computed Tomography Computed TomographyTreatment OutcomeHeterocyclic Compounds, 1-RingLutetiumDipeptidesRetrospective StudiesUrea

Stichwörter der Autor:innen

Metastatic prostate cancerQuantitative SPECT/CTResponse monitoring[177Lu]Lu-PSMA I&T

Substanzen

Prostate-Specific AntigenPSMA I&THeterocyclic Compounds, 1-RingLutetiumDipeptidesUrea

Autor:innen und Institutionen

  • Clinic for Radiology and Nuclear Medicine, University Hospital Basel, Petersgraben 4, 4051, Basel, Switzerland. moritzchristian.neubauer@usb.ch.
  • Clinic for Radiology and Nuclear Medicine, University Hospital Basel, Petersgraben 4, 4051, Basel, Switzerland.
  • Nuclear Medicine and PET-Center, Cantonal Hospital Aarau, Aarau, Switzerland.
  • Nuclear Medicine, University Hospital Bern, Bern, Switzerland.
  • Nuclear Medicine, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.
  • Urology, University Hospital Basel, Basel, Switzerland.

Förderung

  • swissHADRON foundation
  • Siemens Healthineers
  • University of Basel

Zitieren

APA

Neubauer, M. C., Nicolas, G. P., Bauman, A., Fani, M., Nitzsche, E., Afshar-Oromieh, A., Forrer, F., Rentsch, C., Stenner, F., Templeton, A., Schäfer, N., Wild, D., Chirindel, A., & all investigators on behalf of the SSNM Therapy Working Group (2024). Early response monitoring during [177Lu]Lu-PSMA I&T therapy with quantitated SPECT/CT predicts overall survival of mCRPC patients: subgroup analysis of a Swiss-wide prospective registry study. European Journal of Nuclear Medicine and Molecular Imaging, 51(4), 1185-1193. https://doi.org/10.1007/s00259-023-06536-2

Vancouver

Neubauer MC, Nicolas GP, Bauman A, Fani M, Nitzsche E, Afshar-Oromieh A, et al. Early response monitoring during [177Lu]Lu-PSMA I&T therapy with quantitated SPECT/CT predicts overall survival of mCRPC patients: subgroup analysis of a Swiss-wide prospective registry study. European Journal of Nuclear Medicine and Molecular Imaging. 2024;51(4):1185-1193. doi:10.1007/s00259-023-06536-2

BibTeX
@article{Neubauer2024,
  author = {Neubauer, Moritz C and Nicolas, Guillaume P and Bauman, Andreas and Fani, Melpomeni and Nitzsche, Egbert and Afshar-Oromieh, Ali and Forrer, Flavio and Rentsch, Cyril and Stenner, Frank and Templeton, Arnoud and Schäfer, Niklaus and Wild, Damian and Chirindel, Alin and all investigators on behalf of the SSNM Therapy Working Group, all investigators on behalf of the SSNM Therapy Working Group},
  title = {Early response monitoring during [177Lu]Lu-PSMA I&T therapy with quantitated SPECT/CT predicts overall survival of mCRPC patients: subgroup analysis of a Swiss-wide prospective registry study},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2024},
  volume = {51},
  number = {4},
  pages = {1185--1193},
  doi = {10.1007/s00259-023-06536-2}
}
Kostenlos starten →